A multi-site study found cfDNA screening achieves 94.4% sensitivity for fetal risk assessment without partner testing, supporting its routine use in general-risk pregnancies.
Read More
Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience will collaborate on a two-year, 2,000-patient liquid biopsy lung cancer screening project in Japan, using cfDNA and cfRNA testing.
Read More
Researchers have developed an AI model that analyzes whole slide histopathology images to predict TP53 mutations, cancer subtypes, and survival outcomes across 32 solid tumor types.
Read More
Algocyte has launched the PROXIMA Mobile Health Station, a portable device that uses AI and sensors for at-home blood analysis from finger-prick samples, with UKCA regulatory approval and ongoing evaluation.
Read More
VolitionRx reports progress in licensing talks with over 12 diagnostic firms and advances in clinical and veterinary assays, including a reimbursement submission for its Nu.Q Lung Cancer test and a feline lymphoma study milestone.
Read More